id: NEW:buprenorphine_treatment_access_to_opioid_use_disorder
name: Buprenorphine Treatment Access and Prescription â†’ Opioid Use Disorder
from_node:
  node_id: NEW:buprenorphine_treatment_access
  node_name: Buprenorphine Treatment Access and Prescription
to_node:
  node_id: opioid_use_disorder
  node_name: Opioid Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Buprenorphine as a mu-opioid partial agonist reduces opioid cravings and withdrawal symptoms'
- 'Step 2: Medication-assisted treatment enables stabilization and engagement in recovery services'
- 'Step 3: Treatment response (measured by negative urine drug screens) indicates reduced illicit opioid
  use'
- 'Step 4: Sustained treatment adherence improves long-term recovery outcomes'
evidence:
  quality_rating: B
  n_studies: 3
  primary_citation: Christal N Davis et al. 2025. "Multi-ancestry genome-wide association meta-analysis
    of buprenorphine treatment response.." https://doi.org/10.1038/s41386-025-02117-z
  supporting_citations:
  - VA Million Veteran Program clinical data on OUD treatment outcomes
  - Extended-release buprenorphine clinical trial data
  - Additional citations require full-text access
  doi: 10.1038/s41386-025-02117-z
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Investigation of factors affecting buprenorphine treatment response in opioid use disorder,
  with the goal of identifying clinical and genetic predictors to improve treatment outcomes.
quantitative_effects:
  sample_size: 4690
spatial_variation:
  varies_by_geography: true
  variation_notes: VA healthcare system provides a specific structural context; treatment access and outcomes
    likely vary by geographic availability of buprenorphine prescribers and state-level medication-assisted
    treatment policies
moderators:
- name: Genetic background
  direction: strengthens
  strength: moderate
  description: Individual genetic variants may modify treatment response, with the study aiming to identify
    predictive markers
- name: Treatment formulation
  direction: strengthens
  strength: moderate
  description: Extended-release buprenorphine formulation included alongside standard formulations may
    affect adherence and response
structural_competency:
  equity_implications: 'This mechanism highlights structural barriers to effective OUD treatment: (1)
    variable access to buprenorphine prescribers across regions, (2) regulatory barriers (X-waiver requirements
    historically), (3) insurance coverage disparities, (4) stigma in healthcare settings affecting treatment
    engagement. The VA system represents a unique structural context with integrated care that may not
    generalize to civilian populations facing greater access barriers.'
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.899418'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
